Search Results 161-170 of 8013 for TNF

1. A Study to Evaluate the Effectiveness and Safety of Glepaglutide in the Treatment of Short Bowel Syndrome - Mayo Clinic

   Unstable biological therapy (e.g., anti-TNF-α, natalizumab, etc.) within 6 months prior to Screening, including significant changes in doses or switch of ...

2. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

   ... tumor necrosis factor (anti-TNF) agents. Patients who have received or are receiving acute, low dose systemic immunosuppressant medications (e.g., ≤ 10 mg ...

3. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer - Mayo Clinic

   A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of ...

4. A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis - Mayo Clinic

   Previous exposure to anti-tumor necrosis factor therapy. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for ...

5. A Study to Evaluate the Safety, Tolerability, and Activity of Escalating Doses of AK002 in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE) - Mayo Clinic

   ... TNF, anti-IL-5, anti-IL-5 receptor, dupilumab, anti-IgE antibodies, omalizumab) or systemic corticosteroids with a daily dose >10 mg of prednisone or ...

6. Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis - Mayo Clinic

   TNF-alpha inhibitors including but not limited to infliximab (Remicade) or ... Recently, antibodies against the proinflammatory cytokine tumor necrosis factor ...

7. A Study to Evaluate the Effectiveness and Safety of TD-1473 in Crohn's Disease - Mayo Clinic

   ... TNF anti-IL-12/IL-23 therapy, or anti-integrin). If subject is currently receiving an oral corticosteroid, subject is eligible if: the subject has been on ...

8. Neurology - Clinical trials - Mayo Clinic

   Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...

9. Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer - Mayo Clinic

   ... tumor necrosis factor [anti-TNF] agents) within 4 weeks prior to cycle 1, day 1; exceptions: (1) patients may have received acute, low dose, systemic ...

10. A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to randomization. Patients who have received acute, low-dose (≤ 10 mg oral prednisone or ...